Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Alemtuzumab is the active agent of a drug called Lemtrada®. In the European Union, Lemtrada®
is approved for the treatment of a particular form of multiple sclerosis (the so called
relapsing remitting form). The excellent efficacy of the drug justifies its administration
albeit a high risk of considerable side effects. In this context, so called secondary
(occurring after the administration of Lemtrada®) autoimmune diseases are of particular
importance. In these diseases the immune system acts against structures of the body itself;
the reasons are still unknown. Autoimmune diseases may even occur several years after
treatment with Lemtrada®. Therefore, patients who once received the drug need to undergo
intensive long term health monitoring.
This study aims to elucidate which mechanisms cause to the positive and negative effects of
Lemtrada®.
The study includes patients only, who suffer from multiple sclerosis and are indicated to be
treated with Lemtrada®. All patients receive the drug according to the official
recommendations.